Noncoding RNAs and atherosclerosis

Current Atherosclerosis Reports

Volumn 16, Issue 5, 2014, Pages

  Aryal, Binod ^a   Rotllan, Noemi ^a   Fernández Hernando, Carlos ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Lipid metabolism; Long noncoding RNA; MicroRNA

Indexed keywords

LONG UNTRANSLATED RNA; MICRORNA; SMALL UNTRANSLATED RNA; UNTRANSLATED RNA;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; LIPOPROTEIN METABOLISM; MACROPHAGE ACTIVATION; RNA DEGRADATION; RNA SEQUENCE; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; ANIMAL; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; RNA, UNTRANSLATED;

EID: 84895775615     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0407-3     Document Type: Article

References (115)

1. Carninci P et al. The transcriptional landscape of the mammalian genome. Science. 2005;309:1559.
2. Birney E et al. Identification and analysis of functional elements in 1 % of the human genome by the ENCODE pilot project. Nature. 2007;447:799.
3. Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15(Spec No 1):R17.
4. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861.
5. Iaconetti C, Gareri C, Polimeni A, Indolfi C. Non-coding RNAs: the "dark matter" of cardiovascular pathophysiology. Int J Mol Sci. 2013;14:19987.
6. Fire A et al. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature. 1998;391:806.
7. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23:175.
8. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev. 2011;91:827.
9. Fernandez-Hernando C, Ramirez CM, Goedeke L, Suarez Y. MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol. 2013;33:178.
10. Go AS et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2013. doi:10.1161/01.cir. 0000441139.02102.80.
11. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104:503.
12. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23:1494.
13. Djebali S et al. Landscape of transcription in human cells. Nature. 2012;489:101.
14. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522.
15. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005;4:1179.
16. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15.
17. Rossi JJ. RNAi and the P-body connection. Nat Cell Biol. 2005;7:643.
18. Faehnle CR, Joshua-Tor L. Argonaute MID domain takes centre stage. EMBO Rep. 2010;11:564.
19. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597.
20. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193:651.
21. Ma L, Bajic VB, Zhang Z. On the classification of long noncoding RNAs. RNA Biol. 2013;10:925.
22. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155.
23. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol. 2013;20:300.
24. Hu W, Yuan B, Flygare J, Lodish HF. Long noncoding RNAmediated anti-apoptotic activity in murine erythroid terminal differentiation. Genes Dev. 2011;25:2573.
25. Leung A et al. Novel long noncoding RNAs are regulated by angiotensin II in vascular smooth muscle cells. Circ Res. 2013;113:266.
26. Grote P et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell. 2013;24:206.
27. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904.
28. Tiffany HL, Gao JL, Roffe E, Sechler JM, Murphy PM. Characterization of Fpr-rs8, an atypical member of the mouse formyl peptide receptor gene family. J Innate Immun. 2011;3:519.
29. Tsai MC et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329:689.
30. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13:239.
31. Esau C et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3:87.
32. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol. 2008;48:648.
33. Rayner KJ et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570.
34. Ramirez CM et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol. 2011;31:2707.
35. Kim J et al. miR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression. Exp Neurol. 2011;235:476.
36. Ramirez CM et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res. 2013;112:1592.
37. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA. 2010;107:12228.
38. -/- mice - brief report. Arterioscler Thromb Vasc Biol. 2013;33:1973.
39. Rayner KJ et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404.
40. Rayner KJ et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121:2921.
41. Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med. 2013;19:892.
42. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A. 2008;105:1516.
43. Zernecke A et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2:ra81.
44. Zhou J et al. Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress. Circ Res. 2013;113:40.
45. Suarez Y, Wang C, Manes TD, Pober JS. Cutting edge: TNFinduced microRNAs regulate TNF-induced expression of Eselectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol. 2010;184:21.
46. Raitoharju E et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis. 2011;219:211.
47. Ji R et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res. 2007;100:1579.
48. Zhou J et al. MicroRNA-21 targets peroxisome proliferatorsactivated receptor-α in an autoregulatory loop to modulate flowinduced endothelial inflammation. Proc Natl Acad Sci U S A. 2011;108:10355.
49. Di Bernardini E et al. Endothelial lineage differentiation from induced pluripotent stem cells is regulated by microRNA-21 and transforming growth factor beta2 (TGF-β2) pathways. J Biol Chem. 2013. 10.1074/jbc.M113.495531.
50. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF. MicroRNA-10a regulation of proinflammatory phenotype in atherosusceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A. 2010;107:13450.
51. Sun X et al. MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J Clin Invest. 2012;122:1973.
52. Sun X et al. Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res. 2014;114:32.
53. Cheng HS et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med. 2013;5:949.
54. Poliseno L et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood. 2006;108:3068.
55. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res. 2007;100:1164.
56. Zhu N et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis. 2011;215:286.
57. Dentelli P et al. microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol. 2010;30:1562.
58. Son DJ et al. The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nat Commun. 2013;4:3000.
59. Suarez Y et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A. 2008;105:14082.
60. Fang Y, Davies PF. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol. 2012;32:979.
61. Loyer X et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res. 2013. doi:10. 1161/CIRCRESAHA.114.302213.
62. Chen WJ, Yin K, Zhao GJ, Fu YC, Tang CK. The magic and mystery of microRNA-27 in atherosclerosis. Atherosclerosis. 2012;222:314.
63. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res. 2007;101:59.
64. Akhtar N et al. MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes. Arthritis Rheum. 2010;62:1361.
65. Urbich C et al. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood. 2012;119:1607.
66. Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci. 2008;29:12.
67. Menghini R et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation. 2009;120:1524.
68. Ito T, Yagi S, Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun. 2010;398:735.
69. Vasa-Nicotera M et al. miR-146a is modulated in human endothelial cell with aging. Atherosclerosis. 2011;217:326.
70. Wang M et al. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol. 2011;31:2044.
71. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008;454:56.
72. Sarkar J et al. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol. 2010;299:L861.
73. Boettger T et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest. 2009;119:2634.
74. Cheng Y et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009;105:158.
75. Cordes KR et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460:705.
76. Xin M et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23:2166.
77. Quintavalle M, Elia L, Condorelli G, Courtneidge SA. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol. 2010;189:13.
78. Qiu LX et al. The association between common genetic variant of microRNA-146a and cancer susceptibility. Cytokine. 2011;56:695.
79. Chen J et al. Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation. Arterioscler Thromb Vasc Biol. 2011;31:368.
80. Xie C et al. MicroRNA-1 regulates smooth muscle cell differentiation by repressing Kruppel-like factor 4. Stem Cells Dev. 2011;20:205.
81. Torella D et al. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res. 2011;109:880.
82. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res. 2007;101:1225.
83. Zhang P et al. Inhibition of microRNA-29 enhances elastin levels in cells haploinsufficient for elastin and in bioengineered vessels - brief report. Arterioscler Thromb Vasc Biol. 2012;32:756.
84. Liu X et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res. 2009;104:476.
85. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem. 2009;284:3728.
86. Zhang Y et al. Insulin promotes vascular smooth muscle cell proliferation via microRNA-208-mediated downregulation of p21. J Hypertens. 2011;29:1560.
87. Choe N et al. The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. Atherosclerosis. 2013;229:348.
88. Yu ML et al. Vascular smooth muscle cell proliferation is influenced by let-7d microRNA and its interaction with KRAS. Circ J. 2011;75:703.
89. Chen KC et al. Negative feedback regulation between microRNA let-7 g and the oxLDL receptor LOX-1. J Cell Sci. 2011;124:4115.
90. Zhang Y, Chen N, Zhang J, Tong Y. Hsa-let-7 g miRNA targets caspase-3 and inhibits the apoptosis induced by ox-LDL in endothelial cells. Int J Mol Sci. 2013;14:22708.
91. Liao YC et al. Let-7 g improves multiple endothelial functions through targeting TGF-β and SIRT-1 signaling. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.09.069.
92. Liao XB et al. MiR-133a modulates osteogenic differentiation of vascular smooth muscle cells. Endocrinology. 2013;154:3344.
93. Remus EWet al. miR181a protects against angiotensin II-induced osteopontin expression in vascular smooth muscle cells. Atherosclerosis. 2013;228:168.
94. Xu J et al. MiR-9 reduces human acyl-coenzyme A:cholesterol acyltransferase-1 to decrease THP-1 macrophage-derived foam cell formation. Acta Biochim Biophys Sin (Shanghai). 2013;45:953.
95. Thulin P et al. MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor δ in human monocytes during the inflammatory response. Int J Mol Med. 2013;31:1003.
96. Chen T et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDLstimulated monocyte/macrophages. Cardiovasc Res. 2009;83:131.
97. Huang RS, Hu GQ, Lin B, Lin ZY, Sun CC. MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J Investig Med. 2010;58:961.
98. Nazari-Jahantigh M et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest. 2012;122: 4190.
99. Donners MM et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One. 2012;7:e35877.
100. Yang K et al. MiR-146a inhibits oxidized low-density lipoproteininduced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett. 2011;585:854.
101. Liu G et al. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci USA. 2009;106:15819.
102. Ishii Net al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet. 2006;51: 1087.
103. McPherson R et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488.
104. Helgadottir A et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491.
105. Samani NJ et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443.
106. Yap KL et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38:662.
107. Kotake Yet al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011;30:1956.
108. Holdt LM et al. Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet. 2013;9: e1003588.
109. Bochenek G et al. The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. Hum Mol Genet. 2013;22:4516.
110. Robb GB et al. Post-transcriptional regulation of endothelial nitricoxide synthase by an overlapping antisense mRNA transcript. J Biol Chem. 2004;279:37982.
111. Fish JE et al. Hypoxia-inducible expression of a natural cisantisense transcript inhibits endothelial nitric-oxide synthase. J Biol Chem. 2007;282:15652.
112. Li K et al. A noncoding antisense RNA in tie-1 locus regulates tie-1 function in vivo. Blood. 2010;115:133.
113. Halley P et al. Regulation of the apolipoprotein gene cluster by a long noncoding RNA. Cell Rep. 2014;6:222.
114. Lund-Katz S, Phillips MC. High density lipoprotein structurefunction and role in reverse cholesterol transport. Subcell Biochem. 2010;51:183.
115. Carpenter S et al.A long noncoding RNAmediates both activation and repression of immune response genes. Science. 2013;341:789.